AFMD News and Press, Affimed N.V. From 11/10/20

Affimed N.V. (AFMD) Q3 2020 Earnings Conference Call November 10, 2020 08:30 ET Company Participants Alexander Fudukidis - Head, Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Denise Mueller - Chief Business Officer Wolfgang Fischer - Chief Op...

Image source: The Motley Fool. Affimed N.V. (NASDAQ: AFMD) Q3 2020 Earnings Call Nov 10, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Affimed N.V. (AFMD) Q3 2020 Earnings Call Transcript

Are These The Best Penny Stocks To Trade On Tuesday? Most penny stocks today don’t usually carry analyst ratings, in general. Or at least that’s what popular opinion might assume. Regardless of what’s popular, the fact remains that there are hundreds of penny st...

Affimed N.V. (AFMD) Q3 2020 Earnings Conference Call November 10, 2020 8:20 A.M. ET Company Participants Alexander Fudukidis - Head, Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Denise Mueller - Chief Business Officer Wolfgang Fischer - Chie...

Affimed ([[AFMD]] +10.3%) Q3 results:Revenue of €10.6M (+402.4% Y/Y).Operating Loss: (€2.9M) (+76.6%); Net Loss: (€6.0M) (+44.9%); Loss Per Share: (€0.07) (+58.8%).Quick Assets: €97.3M, with anticipated cash runway into 1H of 2023.Upcomin...

Greenland Technologies Holding (GTEC) +88% on launching integrated electric drivetrain.Trxade Group (MEDS) +70%.Summit Wireless Technologies (WISA) +42% on Q4 guidance.Mogo (MOGO) +27% on Q3 results.Fulgent Genetics (FLGT) +16% on Q3 results.Affime...

Affimed N.V. (AFMD) inks a licensing and collaboration agreement with Roivant Sciences aimed at developing and commercializing novel innate cell engager ((ICE)) molecules in oncology.Roivant will in-license preclinical-stage AFM32. The partnership will leverage AFMD's proprietary Redirected O...

Affimed to grant license to AFM32 with options for additional ICE ® molecules directed against targets not included in Affimed’s current pipeline Affimed to receive $60 million in upfront consideration and up to an additional $2 billion in future milestones...

Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020 Heidelberg, Germany, November 9, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giv...

Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets Proof of concept, preclinical assessment to establish activity and feasibility of the comb...